Skip to main content
. Author manuscript; available in PMC: 2010 Sep 29.
Published in final edited form as: J Neuroimmunol. 2009 Aug 6;214(1-2):67–77. doi: 10.1016/j.jneuroim.2009.06.023

Figure 9.

Figure 9

GPR30 agonist treatment reduced CNS cytokine expression. SJL mice (5–7 weeks old) were immunized s.c. with 50 μg PLP139-151 and CFA (400 μg Mycobacterium tuberculosis). Draining lymph node cells were harvested after 7 days and re-stimulated with 50 μg/mL PLP139-151 in the presence of 3 μM G-1 agonist or control DMEM medium with 5% FCS and 0.1% DMSO. When the control group showed peak clinical disease, three representative mice from each group were harvested and the CNS tissue was analyzed for the presence of CCL2 (A) and IL-23 (B) by ELISA. The group that received G-1-treated cells showed significantly decreased CNS CCL2 and IL-23 compared to recipients of control-treated cells (*, p<0.05). C) Purified CD4+ T cells were stimulated in vitro with immobilized anti-CD3 and anti-CD28 in the presence or absence of 3 μM G-1 under normal and polarizing conditions. Polarizing conditions included IL-12 and anti-IL-4 for Th1 (IFN-γ) and TGF-β, IL-6 and IL-23 for Th17 (IL-17). The data indicate no effect of G-1 on T cell cytokine secretion.